Auskünfte zu Addex Therapeutics Ltd
Bonitätsauskunft
Einschätzung der Bonität mit einer Ampel als Risikoindikator und weiteren hilfreichen Firmeninformationen.Mehr erfahren
Beteiligungsauskunft
Erfahren Sie, an welchen nationalen und internationalen Firmen die Aktiengesellschaft, für die Sie sich interessieren, noch beteiligt ist.Mehr erfahren
Firmendossier als PDF
Kontaktinformationen, Veränderungen, Umsatz- und Mitarbeiterzahlen, Management, Besitzverhältnisse, Beteiligungsstruktur und weitere Firmendaten.Jetzt kostenlos abrufen
Über Addex Therapeutics Ltd
- Addex Therapeutics Ltd aus Plan-les-Ouates ist im Bereich «Unternehmensführung und Verwaltung» tätig und aktiv.
- Im Management sind 6 aktive Personen eingetragen. Gegründet wurde die Firma am 19.03.2007.
- Die Firma änderte den Handelsregistereintrag zuletzt am 03.06.2025, unter Meldungen finden Sie alle Änderungen.
- Im Handelsregister ist die Firma Addex Therapeutics Ltd unter UID CHE-113.514.094 eingetragen.
- Es sind 11 weitere aktive Firmen an der gleichen Adresse eingetragen. Dazu gehören: Acqiris SA, Addex Pharma SA, ANTION BIOSCIENCES SA.
Management (6)
neueste Verwaltungsräte
Isaac Manke,
Jason Nunn,
Roger Mills,
Vincent Lawton,
Timothy Dyer
neuste Zeichnungsberechtigte
Isaac Manke,
Jason Nunn,
Roger Mills,
Vincent Lawton,
Timothy Dyer
Handelsregisterinformationen
Eintrag ins Handelsregister
19.03.2007
Rechtsform
Aktiengesellschaft
Rechtssitz der Firma
Plan-les-Ouates
Handelsregisteramt
GE
Handelsregister-Nummer
CH-660.0.659.007-3
UID/MWST
CHE-113.514.094
Branche
Unternehmensführung und Verwaltung
Firmenzweck (Originalsprache)
Acquisition, détention, gestion, aliénation et financement de participations dans toutes sociétés ou entreprises à l'exclusion de participations immobilières, sauf dans les cas où la législation suisse le permet.
Revisionsstelle
Aktive Revisionsstelle (1)
Name | Ort | Seit | Bis | |
---|---|---|---|---|
BDO SA | Vernier | 16.06.2020 |
Frühere Revisionsstelle (1)
Name | Ort | Seit | Bis | |
---|---|---|---|---|
PricewaterhouseCoopers SA | Genève | 23.03.2007 | 15.06.2020 |
Weitere Firmennamen
Frühere und übersetzte Firmennamen
- Addex Therapeutics SA
- Addex Pharmaceuticals Ltd
Zweigniederlassungen (0)
Besitzverhältnisse
Beteiligungen
Neueste SHAB-Meldungen: Addex Therapeutics Ltd
Neueste Meldungen vom Schweizerischen Handelsamtsblatt (SHAB) sind nur in der Originalsprache des jeweiligen Handelsregisteramtes verfügbar. Alle Meldungen ansehen
Publikationsnummer: UP04-0000007261, Handelsregister-Amt Zürich
Category: Notifications issued to company members/nSub-category: Invitation to the General Meeting/nPublication date: SHAB 03.06.2025/nPublicly viewable until: 03.06.2026/nPublication number: UP04-0000007261/nPublishing entity/nHomburger AG, Hardstrasse 201.
8005 Zürich/nInvitation to the ordinary general meeting Addex/nTherapeutics Ltd/nOrganisation concerned:
/nAddex Therapeutics Ltd/nCHE-113.514.094/nc/o: Addex Pharma SA/nchemin des Aulx 12/n1228 Plan-les-Ouates/nGeneral meeting details:/n24.06.2025, 11.00 Uhr.
Addex Therapeutics Ltd/nCampus Biotech/nChemin des Mines 9/nCH-1202 Geneva/nInvitation/Agenda:
/nInvitation to the Annual General Meeting of Addex Therapeutics Ltd. The full text of the/ninvitation is included in the attached PDF./nPlan-les-Ouates, June 3, 2025/nTo the shareholders of Addex Therapeutics Ltd/nNotice of the Annual General Meeting 2025/nTuesday, 24 June 2025.
11:
00 a.m. CEST at Addex Therapeutics Ltd, Campus/nBiotech, Chemin des Mines 9, CH-1202 Geneva (doors open at 10:30 a.m.)./nAgenda/n1. Approval of the Annual Report, the Annual Financial Statements and the/nConsolidated Financial Statements for the business year 2024/n2. Consultative vote on the Compensation Report for the business year 2024/n3. Appropriation of the results/n4. Discharge of the members of the Board of Directors and of the Executive/nManagement/n5. Re-elections of the members of the Board of Directors and re-election of the/nChairman of the Board of Directors/n5.1. Re-election of Vincent Lawton as member and Chairman of the Board/nof Directors/n5.1. Re-election of Raymond Hill as member of the Board of Directors/n5.1. Re-election of Timothy Dyer as member of the Board of Directors/n5.1. Re-election of Roger Mills as member of the Board of Directors/n5.1. Re-election of Jake Nunn as member of the Board of Directors/n5.1. Re-election of Isaac Manke as member of the Board of Directors/n6. Re-elections of the members of the Compensation Committee/n6.1. Re-election of Vincent Lawton as member of the Compensation/nCommittee/n6.1. Re-election of Raymond Hill as member of the Compensation Committee/n7. Re-election of the Auditors/n8. Re-election of the Independent Voting Rights Representative/n9. Approval of the compensation of the members of the Board of Directors and/nof the Executive Management/n9.1. Compensation of the members of the Board of Directors/n9.1. Compensation of the members of the Executive Management/n10. Miscellaneous/nPlan-les-Ouates, June 3, 2025/nTo the shareholders of Addex Therapeutics Ltd/ntice of the Annual General Meeting 2025/nTuesday, 24 June 2025.
11:
00 a.m. CEST at Addex Therapeutics Ltd, Campus Biotech, Chemin des/nMines 9, CH-1202 Geneva (doors open at 10:30 a.m.)./nAgenda/n1. Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial/nStatements for the business year 2024/n2. Consultat ve vote on the Compensation Report for th usiness year 2024/n3. Appropriation of the results/n4. Discharge of the members of the Board of Directors and of the Executive Management/n5. Re-elections of the members of the Board of Directors and re-election of the Chairman of the Board/nof Directors/n5.1. Re-election of Vincent Lawton as member and Chairman of the Board of Directors/n5.2. Re-election of Raymond Hill as member of the Board of Directors/n5.3. Re-election of Ti othy Dyer as member of the Board of Directors/n5.4. Re-election of Roger Mills as member of the Board of Directors/n5.5. Re-election of Jake Nunn as member of the Board of Directors/n5.6. Re-election of Isaac Manke as member of the Board of Directors/n6. Re-elections of the members of the Compens tion Committee/n6.1. Re-election of Vincent Lawton as member of the Compensation Committee/n6.2. Re-election of Raymond Hill as member of the Compensation Committee/n7. Re-election of the Auditors/n8. Re-election of the Independent Voting Rights Representative/n9. Approval of the compensation of the members of the Board of Directors and of the Executive/nManagement/n9.1. ompensation of the members of the Board of Directors/n9.2. Compensation of the members of the Executive Management/n10. Miscellaneous/nMotions and Explanations/n1. Approval of the Annual Report, the Annual Financial Statements and the/nConsolidated Financial Statements for the business year 2024/nThe Board of Directors proposes to approve the Annual Report, the Annual/nFinancial Statements and the Consolidated Financial Statements for the busi-/nness year 2024./nExplanation/nAccording to Article 698 paragraph 2 items 3 and 4 of the Swiss Code of Ob-/nligations (CO) and our Articles of Association, the Annual General Meeting is/nresponsible for approving the Annual Report, the Annual Financial Statements/nand the Consolidated Financial Statements./n2. Consultative vote on the Compensation Report for the business year 2024/nThe Board of Directors proposes to endorse the Compensation Report 2024./nThis vote is consultative./nExplanation/nAccording to Article 735 paragraph 3 item 4 CO, the Board of Directors submits/nthe Compensation Report 2024 to a consultative vote of the shareholders. The/nCompensation Report 2024 has been made available to shareholders and can/nbe downloaded from the company's website: https://www.addextherapeutics.com//nen/investors/financial-reports/. It explains the governance framework and the/nprinciples underlying the compensation structure at the Company. In addition,/nthe Compensation Report 2024 sets out the remuneration of the Board of Di-/nrectors and the Executive Management for 2024, as required under the CO./n3. Appropriation of the results/nThe Board of Directors proposes to carry forward the entire net profit of/nCHF 8,205,559 for the business year 2024 to offset prior losses./nExplanation/nAccording to Article 698 paragraph 2 item 4 CO and our Articles of Association,/nthe Annual General Meeting is responsible for approving the appropriation of/nretained earnings or net loss. The Board of Directors proposes to carry forward/nthe entire net profit of CHF 8,205,559 to offset prior losses./n4. Discharge of the members of the Board of Directors and of the Executive/nManagement/nThe Board of Directors proposes that discharge be granted to the members of/nthe Board of Directors and the Executive Management for their activities in the/nbusiness year 2024./nExplanation/nAccording to Article 698 paragraph 2 item 7 CO and our Articles of Association,/nthe Annual General Meeting is responsible for approving the discharge./n5. Re-elections of the members of the Board of Directors and re-election of/nthe Chairman of the Board of Directors/nThe Board of Directors proposes the re-election of its members Vincent Lawton,/nRaymond Hill, Timothy Dyer, Roger Mills, Jake Nunn and Isaac Manke for a/nterm of one year each;
and the re-election of Vincent Lawton as its Chairman./nExplanation/nAccording to Article 698 paragraph 2 item 2 CO, Article 698 paragraph 3 item 1/nCO and our Articles of Association, the Annual General Meeting is responsible/nfor electing the members of the Board of Directors and the Chairman annually;
/nre-election is possible./n5.1. Re-election of Vincent Lawton as member and Chairman of the Board/nof Directors/nThe Board of Directors proposes to re-elect Vincent Lawton as a mem-/nber of the Board of Directors and as Chairman of the Board of Directors/nfor a term of office extending until completion of the next AGM./n5.2. Re-election of Raymond Hill as member of the Board of Directors/nThe Board of Directors proposes to re-elect Raymond Hill as a member/nof the Board of Directors for a term of office extending until completion of/nthe next AGM./n5.3. Re-election of Timothy Dyer as member of the Board of Directors/nThe Board of Directors proposes to re-elect Timothy Dyer as a member/nof the Board of Directors for a term of office extending until completion of/nthe next AGM./n5.4. Re-election of Roger Mills as member of the Board of Directors/nThe Board of Directors proposes to re-elect Roger Mills as a member of/nthe Board of Directors for a term of office extending until completion of/nthe next AGM./n5.5. Re-election of Jake Nunn as member of the Boar
Publikationsnummer: HR02-1006089764, Handelsregister-Amt Genf, (660)
Addex Therapeutics Ltd, à Plan-les-Ouates, CHE-113.514.094 (FOSC du 22.02.2024, p. 0/1005968669). Radiation de la clause statutaire relative à une augmentation du capital-actions au moyen d'un capital conditionnel introduite par décision du 19.12.2023. L'assemblée générale a introduit une clause statutaire relative à une augmentation du capital-actions au moyen d'un capital conditionnel, par décision du 28.06.2024;
pour les détails, voir les statuts. Radiation de la clause statutaire relative à une marge de fluctuation du capital-actions introduite par décision du 19.12.2023. L'assemblée générale a introduit une clause statutaire relative à une marge de fluctuation du capital-actions par décision du 28.06.2024;
pour les détails, voir les statuts. Statuts modifiés le 28.06.2024.
Publikationsnummer: UP04-0000006382, Handelsregister-Amt Zürich
Category: Notifications issued to company members/nSub-category: Invitation to the General Meeting/nPublication date: SHAB 05.06.2024/nPublicly viewable until: 05.06.2027/nPublication number: UP04-0000006382/nPublishing entity/nHomburger AG, Hardstrasse 201.
8005 Zürich/nInvitation to the ordinary general meeting Addex/nTherapeutics Ltd/nOrganisation concerned:
/nAddex Therapeutics Ltd/nCHE-113.514.094/nc/o: Addex Pharma SA/nchemin des Aulx 12/n1228 Plan-les-Ouates/nGeneral meeting details:/n28.06.2024, 11.00 Uhr, Addex Therapeutics Ltd./nCampus Biotech/nChemin des Mines 9/nCH-1202 Geneva/nInvitation/Agenda:/nInvitation to the Annual General Meeting of Addex Therapeutics Ltd. The full text of the/ninvitation is included in the attached PDF./nPlan-les-Ouates, June 5 2024/nTo the shareholders of Addex Therapeutics Ltd/nNotice of the Annual General Meeting 2024/nFriday, 28 June 2024.
11:
00 a.m. CEST at Addex Therapeutics Ltd, Campus Biotech, Chemin des Mines/n9, CH-1202 Geneva (doors open at 10:30 a.m.)./nAgenda/n1. Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial/nStatements for the business year 2023/n2. Consultative vote on the Compensation Report for the business year 2023/n3. Appropriation of the results/n4. Discharge of the members of the Board of Directors and of the Executive Management/n5. Re-elections of the members of the Board of Directors and re-election of the Chairman of the Board/nof Directors/n5.1. Re-election of Vincent Lawton as member and Chairman of the Board of Directors/n5.2. Re-election of Raymond Hill as member of the Board of Directors/n5.3. Re-election of Timothy Dyer as member of the Board of Directors/n5.4. Re-election of Roger Mills as member of the Board of Directors/n5.5. Re-election of Jake Nunn as member of the Board of Directors/n5.6. Re-election of Isaac Manke as member of the Board of Directors/n6. Re-elections of the members of the Compensation Committee/n6.1. Re-election of Vincent Lawton as member of the Compensation Committee/n6.2. Re-election of Raymond Hill as member of the Compensation Committee/n7. Re-election of the Auditors/n8. Re-election of the Independent Voting Rights Representative/n9. Amendments to the Articles of Association/n9.1. Increase of the capital band (article 3b of the Articles of Association)/n9.2. Increase of the conditional share capital (article 3c of the Articles of Association)/n9.3. Other amendments to the Articles of Association related to the revised corporate law/n9.3.1. Matters related to shareholders and general meetings/n9.3.1.1. Powers of the shareholders meeting (article 8 of the Articles of Association)/n9.3.1.2. Ordinary and Extraordinary Meeting of shareholders (article 9 of Articles of/nAssociation)/n9.3.1.3. Agenda (article 11 of Articles of Association)/n9.3.2. Attributions of the Board of Directors (article 19 of Articles of Association)/n9.3.3. Compensation and Mandates Outside of the Group/n9.3.3.1. Additional amounts in case of changes in the Executive Management/n(article 28 of Articles of Association)/n9.3.3.2. Agreements with members of the Board of Directors and of the Executive/nManagement (article 29 of the Articles of Association)/n9.3.3.3. Mandates Outside the Group (article 31 of the Articles of Association)/nGelöscht:/nPlan-les-Ouates, 23 February 2018/nTo the shareholders of Addex Therapeutics Ltd/nInvitation to the Extraordinary Ge eral Meeting/nFriday, 16 March 2018.
11:
00 a.m. at Addex Therapeutics Ltd, Campus Biotech, Chemin des Mines 9,/nCH-1202 Geneva (doors open at 10:30 a.m.)./nAgenda/n1. Ordinary Share Capital Increase/n2. Amendments to the Articles of Association/n2.1. Amendment to the allocation of the conditional share capit l and amend ent to article 3c/nof the Articles of Association/n2.2. Adoption of a new article 39 regarding the exemption from the duty make an offer (opting-/nout of mandatory offer rules)/n3. Miscellaneous/n2 of 15/n10. Approval of the compensation of the members of the Board of Directors and of the Executive/nManagement/n10.1. Compensation of the members of the Board of Directors/n10.2. Compensation of the members of the Executive Management/n11. Miscellaneous/n3/n3 of 15/nMotions and Explanations/n1. Approval of the Annual Report, the Annual Financial Statements and the Consolidated/nFinancial Statements for the business year 2023/nThe Board of Directors proposes to approve the Annual Report, the Annual Financial Statements/nand the Consolidated Financial Statements for the business year 2023./nExplanation/nAccording to Article 698 paragraph 2 items 3 and 4 of the Swiss Code of Obligations (CO) and our/nArticles of Association, the Annual General Meeting is responsible for approving the Annual Report,/nthe Annual Financial Statements and the Consolidated Financial Statements./n2. Consultative vote on the Compensation Report for the business year 2023/nThe Board of Directors proposes to endorse the Compensation Report 2023. This vote is consultative./nExplanation/nAccording to Article 735 paragraph 3 item 4 CO, the Board of Directors submits the Compensation/nReport 2023 to a consultative vote of the shareholders. The Compensation Report 2023 has been/nmade available to shareholders and can be downloaded from the company's website:/nhttps://www.addextherapeutics.com/en/investors/financial-reports/. It explains the governance/nframework and the principles underlying the compensation structure at the Company. In addition, the/nCompensation Report 2023 sets out the remuneration of the Board of Directors and the Executive/nManagement for 2023, as required under the CO./n3. Appropriation of the results/nThe Board of Directors proposes to carry forward the loss of CHF 9,752,341 for the business year/n2023./nExplanation/nAccording to Article 698 paragraph 2 item 4 CO and our Articles of Association, the Annual General/nMeeting is responsible for approving the appropriation of retained earnings or net loss. The Board of/nDirectors proposes that the net loss for the year 2023 be carried forward./n4. Discharge of the members of the Board of Directors and of the Executive Management/nThe Board of Directors proposes that discharge be granted to the members of the Board of Directors/nand the Executive Management for their activities in the business year 2023./nExplanation/nAccording to Article 698 paragraph 2 item 7 CO and our Articles of Association, the Annual General/nMeeting is responsible for approving the discharge./n5. Re-elections of the members of the Board of Directors and re-election of the Chairman of the/nBoard of Directors/nThe Board of Directors proposes the re-election of its members Vincent Lawton, Raymond Hill,/nTimothy Dyer, Roger Mills, Jake Nunn and Isaac Manke for a term of one year each;
and the re-/nelection of Vincent Lawton as its Chairman./nExplanation/nAccording to Article 698 paragraph 2 item 2 CO, Article 698 paragraph 3 item 1 CO and our Articles/nof Association, the Annual General Meeting is responsible for electing the members of the Board of/nDirectors and the Chairman annually;
re-election is possible./n5.1. Re-election of Vincent Lawton as member and Chairman of the Board of Directors/nThe Board of Directors proposes to re-elect Vincent Lawton as a member of the Board of/nDirectors and as Chairman of the Board of Directors for a term of office extending until/ncompletion of the next AGM./n4/n4 of 15/n5.2. Re-election of Raymond Hill as member of the Board of Directors/nThe Board of Directors proposes to re-elect Raymond Hill as a member of the Board of/nDirectors for a term of office extending until completion of the next AGM./n5.3. Re-election of Timothy Dyer as member of the Board of Directors/nThe Board of Directors proposes to re-elect Timothy Dyer as a member of the Board of/nDirectors for a term of office extending until completion of the next AGM./n5.4. Re-election of Roger Mills as member of the Board of Directors/nThe Board of Directors proposes to re-elect Roger Mills as a member of the Board of Directors/nfor a term of office extending until completion of the next AG
Trefferliste
Hier finden Sie eine Verlinkung des Managements auf eine Trefferliste zu Personen mit dem gleichen Namen, die im Handelsregister eingetragen sind.